[1] Hudson BG, Tryggvason K, Sundaramoorthy M, Neilson EG. Alport's syndrome, Goodpasture's syndrome, and type IV collagen. N Engl J Med. 2003;348(25):2543–2556. doi:10.1056/NEJMra022296
[2] Kashtan CE, Segal Y. Genetic disorders of glomerular basement membranes. Nephron Clin Pract 2011; 118: c9-c18.
[3] Fallerini C, Dosa L, Tita R, et al. Unbiased next generation sequencing analysis confirms the existence of autosomal dominant Alport syndrome in a relevant fraction of cases. Clin Genet. 2014;86(3):252–257. doi:10.1111/cge.12258
[4] Morinière V, Dahan K, Hilbert P, et al. Improving mutation screening in familial hematuric nephropathies through next generation sequencing. J Am Soc Nephrol. 2014;25(12):2740–2751. doi:10.1681/ASN.2013080912
[5] Andreas M , Tsielestina P , Constantinos D . Prevalence of clinical, pathological and molecular features of glomerular basement membrane nephropathy caused by COL4A3 or COL4A4 mutations: a systematic review[J]. Clinical Kidney Journal.2020,1-12. doi: 10.1093/ckj/sfz176
[6] Kruegel J, Rubel D, Gross O. Alport syndrome--insights from basic and clinical research. Nat Rev Nephrol. 2013;9(3):170–178. doi:10.1038/nrneph.2012.259
[7] Rumpelt H J, Langer K H, Schärer K, et al. Split and extremely thin glomerular basement membranes in hereditary nephropathy (Alport's syndrome)[J]. Virchows Archiv A, 1974, 364(3):225.
[8] ]Massella L, Gangemi C, Giannakakis K, et al. Prognostic Value of Glomerular Collagen IV Immunofluorescence Studies in Male Patients with X-Linked Alport Syndrome[J]. Clinical Journal of the American Society of Nephrology Cjasn, 2013, 8(5):749.
[9] Hanson H, Storey H, Pagan J, et al. The value of clinical criteria in identifying patients with X-linked Alport syndrome[J]. Clin J Am Soc Nephrol, 2011, 6(1): 198-203.
[10] Nakanishi K, Yoshikawa N. Alport syndrome. Nihon Jinzo Gakkai Shi. 2015;57(4):736–42.
[11] Kashtan C E, Ding J, Garosi G, et al. Alport syndrome: a unified classification of genetic disorders of collagen IV α345: a position paper of the Alport Syndrome Classification Working Group.[J]. Kidney International, 2018.
[12] Gross O, Netzer KO, Lambrecht R, Seibold S, Weber M. Meta-analysis of genotype-phenotype correlation in X-linked Alport syndrome: impact on clinical counselling. Nephrol Dial Transplant. 2002;17(7):1218–1227. doi:10.1093/ndt/17.7.1218
[13] Zhao X, Chen C, Wei Y, et al. Novel mutations of COL4A3, COL4A4, and COL4A5 genes in Chinese patients with Alport Syndrome using next generation sequence technique. Mol Genet Genomic Med. 2019;7(6):e653. doi:10.1002/mgg3.653
[14] Shang S, Peng F, Wang T, et al. Genotype-phenotype correlation and prognostic impact in Chinese patients with Alport Syndrome. Mol Genet Genomic Med. 2019;7(7):e00741. doi:10.1002/mgg3.741
[15] Nozu K, Nakanishi K, Abe Y, et al. A review of clinical characteristics and genetic backgrounds in Alport syndrome. Clin Exp Nephrol. 2019;23(2):158–168. doi:10.1007/s10157-018-1629-4
[16] Said SM, Fidler ME, Valeri AM, et al. Negative Staining for COL4A5 Correlates With Worse Prognosis and More Severe Ultrastructural Alterations in Males With Alport Syndrome. Kidney Int Rep. 2016;2(1):44–52. Published 2016 Sep 29. doi:10.1016/j.ekir.2016.09.056
[17] Hashimura Y, Nozu K, Kaito H, et al. Milder clinical aspects of X-linked Alport syndrome in men positive for the collagen IV α5 chain. Kidney Int. 2014;85(5):1208–1213. doi:10.1038/ki.2013.479
[18] Jais JP, Knebelmann B, Giatras I, et al. X-linked Alport syndrome: natural history and genotype-phenotype correlations in girls and women belonging to 195 families: a "European Community Alport Syndrome Concerted Action" study. J Am Soc Nephrol. 2003;14(10):2603–2610. doi:10.1097/01.asn.0000090034.71205.74
[19] Persikov AV, Pillitteri RJ, Amin P, Schwarze U, Byers PH, Brodsky B. Stability related bias in residues replacing glycines within the collagen triple helix (Gly-Xaa-Yaa) in inherited connective tissue disorders. Hum Mutat. 2004;24(4):330–337. doi:10.1002/humu.20091
[20] Savige J, Ariani F, Mari F, et al. Expert consensus guidelines for the genetic diagnosis of Alport syndrome. Pediatr Nephrol. 2019;34(7):1175–1189. doi:10.1007/s00467-018-3985-4
[21] Matthaiou A, Poulli T, Deltas C. Prevalence of clinical, pathological and molecular features of glomerular basement membrane nephropathy caused by COL4A3 or COL4A4 mutations: a systematic review. Clinical Kidney Journal, 2020, 1-12.doi: 10.1093/ckj/sfz176
[22] Voskarides K, Damianou L, Neocleous V, et al. COL4A3/COL4A4 mutations producing focal segmental glomerulosclerosis and renal failure in thin basement membrane nephropathy. J Am Soc Nephrol. 2007;18(11):3004–3016. doi:10.1681/ASN.2007040444
[23] Mencarelli MA, Heidet L, Storey H, et al. Evidence of digenic inheritance in Alport syndrome. J Med Genet. 2015;52(3):163–174. doi:10.1136/jmedgenet-2014-102822
[24] Fallerini C, Baldassarri M, Trevisson E, et al. Alport syndrome: impact of digenic inheritance in patients management. Clin Genet. 2017;92(1):34–44. doi:10.1111/cge.12919
[25] Charbit M, Gubler M C, Dechaux M, et al. Cyclosporin therapy in patients with Alport syndrome[J]. Pediatric Nephrology, 2007, 22(1):57-63.
[26] Vischini G, Kapp M E, Wheeler F C, et al. A unique evolution of the kidney phenotype in a patient with autosomal recessive Alport syndrome[J]. Human Pathology, 2018.
[27] Li Z, Zhu P, Huang H, et al. Identification of a novel COL4A5 mutation in the proband initially diagnosed as IgAN from a Chinese family with X-linked Alport syndrome. Sci China Life Sci. 2019;62(12):1572–1579. doi:10.1007/s11427-018-9545-3
[28] Savige J, Rana K, Tonna S, et al. Thin basement membrane nephropathy[J]. Kidney International, 2003, 64(4):1169-1178.
[29] Zhang Y, Wang F, Ding J, et al. Long-term treatment by ACE inhibitors and angiotensin receptor blockers in children with Alport syndrome. Pediatr Nephrol. 2016;31(1):67–72. doi:10.1007/s00467-015-3184-5
[30] Gross O, Friede T, Hilgers R, et al. Safety and Efficacy of the ACE-Inhibitor Ramipril in Alport Syndrome: The Double-Blind, Randomized, Placebo-Controlled, Multicenter Phase III EARLY PRO-TECT Alport Trial in Pediatric Patients. ISRN Pediatr. 2012;2012:436046. doi:10.5402/2012/436046
[31] Gross O, Perin L, Deltas C. Alport syndrome from bench to bedside: the potential of current treatment beyond RAAS blockade and the horizon of future therapies. Nephrol Dial Transplant. 2014;29 Suppl 4:iv124–iv130. doi:10.1093/ndt/gfu028
[32] Torra R, Furlano M. New therapeutic options for Alport syndrome. Nephrol Dial Transplant. 2019;34(8):1272–1279. doi:10.1093/ndt/gfz131
[33] Kashtan CE. Renal transplantation in patients with Alport syndrome: patient selection, outcomes, and donor evaluation. Int J Nephrol Renovasc Dis. 2018;11:267–270. Published 2018 Oct 16. doi:10.2147/IJNRD.S150539
[34] Gillion V, Dahan K, Cosyns JP, et al. Genotype and Outcome After Kidney Transplantation in Alport Syndrome. Kidney Int Rep. 2018;3(3):652–660. Published 2018 Feb 2. doi:10.1016/j.ekir.2018.01.008